Payments made for regulatory milestones under a collaboration agreement

No definition available.

Name:	nbix_PaymentsMadeForRegulatoryMilestones
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential development and regulatory milestone payment receipts under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_PotentialDevelopmentAndRegulatoryMilestonePaymentReceipts
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential milestone payment receipts under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestonePaymentReceipts
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Potential milestone payments under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_PotentialMilestonePayments
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Potential payments for commercial milestones under a collaboration agreement..

+ References

No definition available.

+ Details

Name:	nbix_PotentialPaymentsForCommercialMilestones
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential payments for regulatory milestones under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_PotentialPaymentsForRegulatoryMilestones
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement.

+ References

No definition available.

+ Details

Name:	nbix_TerminationNoticePeriod
Namespace Prefix:	nbix_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payments made under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_UpfrontPaymentsMade
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront payments received under a collaboration agreement.

+ References

No definition available.

+ Details

Name:	nbix_UpfrontPaymentsReceived
Namespace Prefix:	nbix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 30
-Section 50
-Paragraph 1A
-Subparagraph (b)(1)(i)
-URI http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729

+ Details

Name:	us-gaap_EquitySecuritiesFvNiRestricted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714

+ Details

Name:	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbix_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_ClinicalDevelopmentRegulatoryAndCommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nbix_RegulatoryApprovalClinicalResultsAndFdaAcceptanceMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nbix_ClinicalDevelopmentAndRegulatoryMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended				3 Months Ended				9 Months Ended		55 Months Ended	112 Months Ended
	Jan. 31, 2019	Feb. 28, 2017	Mar. 31, 2015	Jun. 30, 2010	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Restricted investment in equity securities fair value amount					$ 48,915				$ 48,915		$ 48,915	$ 48,915
Acquired in-process research and development									118,081
Revenues					222,094			$ 151,757	544,077	$ 319,748
Collaboration revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues					24,000			$ 40,466	29,008	$ 40,466
Voyager Therapeutics \| Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payments made	$ 115,000
Restricted investment in equity securities cost	$ 50,000
Share price	$ 11.9625
Restricted investment in equity securities fair value amount							$ 54,700
Collaboration termination notice period	180 days
Voyager Therapeutics \| Collaboration and License Agreement \| IPR&D
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Acquired in-process research and development						$ 5,000	$ 113,100
Voyager Therapeutics \| Collaboration and License Agreement \| Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Restricted investment in equity securities number of shares	4.2
Voyager Therapeutics \| Collaboration and License Agreement \| Development, Regulatory and Commercial Milestone Payment
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payments	$ 1,700,000
B I A L
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payments made		$ (30,000)
Potential payments for regulatory milestones		40,000
Potential payments for commercial milestones		$ 75,000
B I A L \| Regulatory and Clinical Results and FDA Acceptance Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments made for regulatory milestones					10,000				10,000		10,000	10,000
B I A L \| Development and Regulatory Milestone Payments
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments made for regulatory milestones					20,000				$ 20,000		20,000	20,000
Mitsubishi Tanabe
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payments received			$ 30,000								30,000
Potential milestone payment receipts			85,000
Deferred revenues			10,200
Mitsubishi Tanabe \| Collaboration revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues			$ 19,800								$ 15,000
AbbVie
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential payments for commercial milestones				$ 50,000
Upfront payments received				75,000
Potential development and regulatory milestone payment receipts				$ 480,000
AbbVie \| Collaboration revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues					$ 20,000							$ 135,000